Q301--Afirma Thyroid Testing VISN 23
SAM.GOV Due: April 18, 2025 at 04:00 PM UTC
In-Active Special Notice Source Url

Summary

The opportunity titled Q301--Afirma Thyroid Testing VISN 23 is a special notice issued by the Department of Veterans Affairs, specifically the Network Contracting Office 23. This notice indicates the intent to award a sole source, fixed price indefinite delivery contract to Veracyte, Inc. for reference laboratory testing services related to the Afirma Genomic Sequencing Classifier and Afirma Xpression Atlas. These services are crucial for providing comprehensive solutions in the diagnosis and management of thyroid cancer, utilizing minimally invasive fine needle aspiration samples. The contract is aimed at enhancing the capabilities of various VA health care systems across the VISN 23 region. While Veracyte is the primary vendor identified for this requirement, other vendors who believe they can meet the necessary capabilities are invited to submit their interest and qualifications for consideration. This opportunity is particularly suited for businesses specializing in genomic testing and laboratory services, especially those with experience in working with healthcare providers and government contracts.
Description
This is a Notice of Intent published in accordance with Federal Acquisition Regulation (FAR) 5.101(a)(1) requiring the dissemination of information regarding proposed contract actions. This Notice of Intent is for a proposed award of a sole source, fixed price indefinite delivery contract, as implem
Entities
VADO
Department of Veterans Affairs
NAICS
621511
Set Aside
None
Place of Performance
Point of Contact
Full Name Email Phone Type
Logan Gahring [email protected] 319-339-7113 primary
Attachments
  • 36C26325Q0681.docx